On the Record · Prestige Consumer Healthcare
Prestige Consumer Healthcare acquisitions, on the record
The businesses Prestige Consumer Healthcare bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Akorn Operating Company LLC (consumer health business assets)Word for word“On July 1, 2021, we completed the acquisition of the consumer health business assets from Akorn Operating Company LLC ("Akorn") pursuant to an Asset Purchase Agreement, dated May 27, 2021 (the "Purchase Agreement"), for a purchase price of $228.9 million in cash, subject to certain closing adjustments specified in the Purchase Agreement.” 10-K for 2024 | acquisition | July 1, 2021 | $228.9 million |
one of its suppliers (acquired by Australian subsidiary)Word for word“On January 8, 2024, our Australian subsidiary acquired one of its suppliers.” 10-K for 2024 | acquisition | January 8, 2024 | — |
Hydralyte intellectual property (rights in all remaining jurisdictions except the United States)Word for word“(a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us the rights to the Hydralyte intellectual property in all remaining jurisdictions with the exception of the United States.” 10-K for 2025 | acquisition | October 1, 2024 | — |
consumer health business assets from Akorn Operating Company LLCWord for word“In 2022, we acquired the consumer health business assets from Akorn Operating Company LLC.” 10-K for 2025 | acquisition | 2022 | — |
a manufacturing acquisition in Australia (Australian subsidiary acquired one of its suppliers)Word for word“The increase in net cash used in investing activities was primarily due to a manufacturing acquisition in Australia in 2024.” 10-K for 2025 | acquisition | — | — |
Pillar5 Pharma Inc.Word for word“On December 18, 2025, we completed the acquisition of Pillar5, which was funded through a combination of cash on hand and our existing asset-based revolving credit facility.” 10-K for 2026 | acquisition | December 18, 2025 | — |
Foundation Consumer Brands, LLCWord for word“Pending Acquisition of Foundation Consumer Brands Product Portfolio On March 19, 2026, we entered into a definitive agreement to acquire certain assets and assume certain liabilities primarily related to a portfolio of over-the-counter consumer health products, including Breathe Right® and certain other brands from Foundation Consumer Brands, LLC.” 10-K for 2026 | agreed acquisition | March 19, 2026 | — |
FeminaxWord for word“(a) On October 31, 2025, we completed the acquisition of Feminax.” 10-K for 2026 | acquisition | October 31, 2025 | — |
Hydralyte intellectual propertyWord for word“(a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us the rights to the Hydralyte intellectual property in all remaining jurisdictions with the exception of the United States.” 10-K for 2026 | acquisition | October 1, 2024 | — |
one of its suppliers (Australian subsidiary)Word for word“( a) On January 8, 2024, our Australian subsidiary acquired one of its suppliers.” 10-K for 2026 | acquisition | January 8, 2024 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2017-03-31 | $0 | $110.7 million | $268.6 million |
| 2018-03-31 | $0 | $0 | — |
| 2019-03-31 | — | $65.9 million | $0 |
| 2020-03-31 | $2.8 million | $0 | — |
| 2021-03-31 | $0 | $0 | — |
| 2022-03-31 | $247 million | — | $1.6 million |
| 2023-03-31 | $0 | — | — |
| 2024-03-31 | $10.6 million | — | $600,000 |
| 2025-03-31 | $8.3 million | — | $309,000 |
| 2026-03-31 | $123.7 million | — | $52.8 million |
Deal filings since 2016
- 2026-07-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-07-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-06-16 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2026-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-03-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-12-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-07-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-05-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-03-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-07-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-03-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-26 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2016-12-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-02-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-02-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Prestige Consumer Healthcare’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-05-14. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.